Sylvie Lorenzen Selected Research

Sylvie Lorenzen Research Topics

Disease

31	Neoplasms (Cancer) 01/2022 - 01/2008
18	Adenocarcinoma 01/2022 - 09/2007
10	Stomach Neoplasms (Stomach Cancer) 01/2022 - 07/2011
4	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2018
4	Carcinoma (Carcinomatosis) 01/2022 - 10/2010
4	Esophageal Neoplasms (Esophageal Cancer) 12/2021 - 03/2015
4	Neoplasm Metastasis (Metastasis) 10/2021 - 07/2011
4	Breast Neoplasms (Breast Cancer) 06/2020 - 02/2011
3	Microsatellite Instability 01/2022 - 12/2021
1	Mucositis 11/2020
1	Fibrosis (Cirrhosis) 10/2020
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 03/2019
1	Acne Vulgaris 01/2019
1	Exanthema (Rash) 01/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2018
1	Sarcoma (Soft Tissue Sarcoma) 01/2018
1	Osteosarcoma (Osteogenic Sarcoma) 01/2018
1	Necrosis 01/2018
1	Colonic Neoplasms (Colon Cancer) 01/2018
1	Hepatocellular Carcinoma (Hepatoma) 01/2018
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2018
1	Disease Progression 12/2017
1	Lymphatic Metastasis 12/2017
1	Esophageal Squamous Cell Carcinoma 01/2016
1	Lung Neoplasms (Lung Cancer) 01/2015
1	Nausea 02/2009
1	Vomiting 02/2009

Drug/Important Bio-Agent (IBA)

6	Trastuzumab (Herceptin)FDA Link 01/2022 - 07/2011
6	Capecitabine (Xeloda)FDA Link 01/2020 - 03/2015
5	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2018
5	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 12/2011
5	Cetuximab (Erbitux)FDA Link 01/2019 - 12/2011
5	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 02/2009
4	Docetaxel (Taxotere)FDA Link 01/2022 - 12/2016
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 09/2020 - 12/2011
4	Biomarkers (Surrogate Marker)IBA 06/2020 - 03/2011
4	ErbB Receptors (EGF Receptor)IBA 01/2019 - 07/2011
3	Pharmaceutical PreparationsIBA 01/2022 - 04/2014
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 06/2015
3	RamucirumabIBA 01/2022 - 06/2015
3	PlatinumIBA 11/2020 - 01/2020
3	Leucovorin (Folinic Acid)FDA Link 09/2020 - 12/2011
3	Glucose (Dextrose)FDA LinkGeneric 01/2015 - 01/2008
2	IpilimumabIBA 01/2022 - 06/2020
2	pembrolizumabIBA 01/2022 - 01/2022
2	NivolumabIBA 01/2022 - 06/2020
2	Biological ProductsIBA 01/2018 - 01/2015
2	human ERBB2 proteinIBA 03/2015 - 07/2011
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2015 - 01/2008
2	Monoclonal AntibodiesIBA 12/2011 - 07/2011
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	A-Form DNA (A-DNA)IBA 01/2022
1	Circulating Tumor DNAIBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Everolimus FDA Link 11/2020
1	MucinsIBA 10/2020
1	Cytostatic AgentsIBA 01/2020
1	Taxoids (Taxanes)IBA 01/2020
1	Ado-Trastuzumab EmtansineIBA 01/2020
1	Vitamin K 1 (Phylloquinone)FDA LinkGeneric 01/2019
1	Doxycycline (Periostat)FDA LinkGeneric 01/2019
1	VemurafenibIBA 01/2018
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2018
1	PEGPH20IBA 01/2018
1	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 01/2018
1	SirtuinsIBA 01/2018
1	Epirubicin (Ellence)FDA LinkGeneric 12/2016
1	Tyrosine Kinase InhibitorsIBA 03/2015
1	Lapatinib (GW572016)FDA Link 03/2015
1	Cadherins (E-Cadherin)IBA 12/2011
1	pimonidazoleIBA 03/2011
1	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 03/2011
1	vadimezanIBA 03/2011
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2011
1	Aprepitant (Emend)FDA Link 02/2009
1	Integrin alphaVbeta3IBA 01/2008

Therapy/Procedure

16	Drug Therapy (Chemotherapy) 01/2022 - 02/2009
10	Therapeutics 01/2022 - 01/2017
9	Neoadjuvant Therapy 10/2020 - 09/2007
7	Immunotherapy 01/2022 - 01/2018
3	Chemoradiotherapy 09/2020 - 06/2011
2	Induction Chemotherapy 09/2020 - 06/2011
1	Palliative Care (Palliative Therapy) 12/2021
1	Hyperthermic Intraperitoneal Chemotherapy 10/2021
1	Radiotherapy 09/2020
1	Intravenous Infusions 12/2016
1	Combination Drug Therapy (Combination Chemotherapy) 04/2014
1	Aftercare (After-Treatment) 03/2011
1	Molecular Targeted Therapy 01/2008